Akero Therapeutics Inc (AKRO) Return on Investment ROI from the third quarter of 2025 to third quarter of 2024 and for the year 2025, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Akero Therapeutics Inc   (NASDAQ: AKRO)


Akero Therapeutics Inc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Akero Therapeutics Inc's ROI in the third quarter of 2025?
Akero Therapeutics Inc recorded a cumulative net loss of $-293 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -29.99%.

Within the Healthcare sector 407 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 3060 to 3607.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Investment Change TTM 28.02 % 29.08 % 30.29 % 52.93 % 59.03 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 958 1,049 1,113 786 774
Return On Investment (TTM) -29.99 % -30.51 % -30.73 % -30.77 % -31.1 %
AKRO's Overall Ranking # 3607 # 3060 # 2743 # 2213 # 3378
Seq. Investment Change TTM 4.93 % 6.13 % 7.06 % 7.37 % 5.8 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -293 -284 -269 -252 -237

AKRO Company Profile >> Back to AKRO Roi Comparisons >> See Annual AKRO Return On Investment



Return On Investment AKRO's Ranking
Within: No.
Industry # 159
Sector # 408
Overall # 3607

Return On Investment Statistics
High Average Low
-8.37 %
-34.83 %
-65.09 %
  (Jun 30 2022)







Financial Statements
Akero Therapeutics Inc's III. Quarter Investments $ 958 Millions AKRO's Balance sheet
Akero Therapeutics Inc's III. Quarter Income $ -82 Millions Quarterly AKRO's Income Statement
AKRO's Income by Division See AKRO's Income by Division


AKRO Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 786 561 337 170 260
Y / Y Investment Growth 40.09 % 66.27 % 98.03 % -34.51 % 102.12 %
Net Income in Millions -252 -152 -112 -101 -79
Y / Y Net Income Growth - - - - -
Annual Return On Investment -32.06 % -27.04 % -33.2 % -59.13 % -30.44 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AKRO's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AKRO's Competitors
Subscribers only: Roi for Akero Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for AKRO's Customers

Other Ratios
AKRO's Roa AKRO's Inventory Turnover Ratio AKRO's Growth Rates AKRO's Dividend Statistics
AKRO's Profitability Ratios AKRO's Asset Turnover Ratio AKRO's Dividend Growth
AKRO's Roe AKRO's Valuation Ratios AKRO's Financial Strength Ratios AKRO's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector ROI

Date modified: 2026-09-08T15:11:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.